Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
Article in Cancers (May 2023)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Article in Cancers (May 2023)
Article in Trends in Molecular Medicine (May 2022)
Article in International Immunopharmacology (July 2021)